Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - UNIVERSAL BIOSENSORS INC | d619438dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): September 26, 2018
Universal Biosensors, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 000-52607 | 98-0424072 | ||
| (state or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) | ||
| 1 Corporate Avenue Rowville, 3178, Victoria Australia |
Not Applicable | |||
| (address of principal executive offices) | (Zip Code) | |||
Registrant’s telephone number, including area code: +61 3 9213 9000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 7.01 | Regulation FD Disclosure |
On September 25, 2018, Universal Biosensors, Inc. (“UBI”) and its wholly owned subsidiary, Universal Biosensors Pty Ltd (“UBS”) received notice from Cilag GmbH International acting through its LifeScan division (“LifeScan”) of LifeScan’s exercise of its right to convert (or “buyout”) its obligation to pay quarterly service fees to UBS pursuant to the terms of the Master Services and Supply Agreement between UBI, UBS and LifeScan dated October 29, 2007, as amended and restated.
UBI issued a press release on September 26, 2018 announcing the receipt of the notice. A copy of the press release is furnished with this Current Report as Exhibit 99.1 and is incorporated by reference into this Item 7.01.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit No. |
Description | |
| 99.1 | Press Release of Universal Biosensors, Inc. dated September 26, 2018. | |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: September 28, 2018
| UNIVERSAL BIOSENSORS, INC. | ||
| By: | /s/ Cameron Billingsley | |
| Name: | Cameron Billingsley | |
| Title: | Company Secretary | |